Kirby McInerney probes Unicycive after FDA letter sent shares down 39%

The law firm said it is investigating potential federal securities law violations after Unicycive disclosed a second Complete Response Letter tied to the same manufacturing deficiencies cited in June 2025.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.